Cefoxitin

CHEMBL996 Phase 4 معتمد Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

427.5 g/mol

LogP

—

Phase

4

A cephamycin antibiotic with strong anaerobic coverage, commonly used for intra-abdominal, pelvic, and mixed aerobic-anaerobic infections as well as surgical prophylaxis. It is highly resistant to beta-lactamases produced by anaerobic bacteria. Its coverage profile makes it particularly suited to procedures involving the bowel or female pelvic organs.

الوزن الجزيئي

427,5000 g/mol

LogP

0,00

TPSA

202,00 Å²

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Infectious Disease Pancreatic Cancer Colorectal Cancer

آلية العمل

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell …

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

CO[C@@]1(NC(=O)Cc2cccs2)C(=O)N2C(C(=O)O)=C(COC(N)=O)CS[C@@H]21

InChI

InChI=1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1

Molecular Formula

C16H17N3O7S2

HBD / HBA

3 / 9

الروابط القابلة للدوران

8

الذرات الثقيلة

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

A cephamycin antibiotic with strong anaerobic coverage, commonly used for intra-abdominal, pelvic, and mixed aerobic-anaerobic infections as well as surgical prophylaxis. It is highly resistant to beta-lactamases produced by anaerobic bacteria. Its coverage profile makes it particularly suited to procedures involving the bowel or female pelvic organs.

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Yes, Cefoxitin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL996. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 441199. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Cefoxitin على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C16H17N3O7S2
المرادفات: 1

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.